Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

BADALAMENTI, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.296
EU - Europa 3.984
AS - Asia 1.658
SA - Sud America 304
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 11
OC - Oceania 5
Totale 15.316
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.256
IT - Italia 1.243
SG - Singapore 757
DE - Germania 698
FI - Finlandia 634
CN - Cina 619
UA - Ucraina 439
BR - Brasile 266
IE - Irlanda 216
GB - Regno Unito 215
RU - Federazione Russa 112
SE - Svezia 100
BE - Belgio 60
IN - India 58
RO - Romania 58
NL - Olanda 49
AT - Austria 46
FR - Francia 40
IR - Iran 32
TR - Turchia 30
CI - Costa d'Avorio 26
KR - Corea 26
UZ - Uzbekistan 19
CA - Canada 18
IQ - Iraq 18
HK - Hong Kong 17
MA - Marocco 13
MX - Messico 13
BG - Bulgaria 12
CL - Cile 11
CH - Svizzera 10
AR - Argentina 8
CZ - Repubblica Ceca 8
JP - Giappone 8
PL - Polonia 8
BD - Bangladesh 7
EU - Europa 7
LT - Lituania 7
MY - Malesia 7
EG - Egitto 6
GR - Grecia 6
AL - Albania 5
AU - Australia 5
ES - Italia 5
JO - Giordania 5
VE - Venezuela 5
VN - Vietnam 5
AE - Emirati Arabi Uniti 4
KE - Kenya 4
KZ - Kazakistan 4
PE - Perù 4
PH - Filippine 4
AZ - Azerbaigian 3
BH - Bahrain 3
CY - Cipro 3
EC - Ecuador 3
ID - Indonesia 3
JM - Giamaica 3
MM - Myanmar 3
NO - Norvegia 3
PK - Pakistan 3
UY - Uruguay 3
ZA - Sudafrica 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BO - Bolivia 2
BY - Bielorussia 2
CO - Colombia 2
CR - Costa Rica 2
DK - Danimarca 2
GH - Ghana 2
KG - Kirghizistan 2
LB - Libano 2
MN - Mongolia 2
NP - Nepal 2
PS - Palestinian Territory 2
TN - Tunisia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
OM - Oman 1
PT - Portogallo 1
SA - Arabia Saudita 1
SV - El Salvador 1
SY - Repubblica araba siriana 1
Totale 15.316
Salva come PNG Salva come JPEG
Città #
Fairfield 1.344
Ashburn 852
Chandler 745
Woodbridge 725
Houston 645
Wilmington 582
Seattle 493
Singapore 485
Ann Arbor 471
Cambridge 418
Palermo 312
Jacksonville 241
Medford 234
Dublin 210
Des Moines 187
Boardman 161
Princeton 144
Altamura 127
San Diego 124
Lawrence 112
Nanjing 109
Helsinki 106
Munich 100
Rome 97
New York 95
Ludwigshafen am Rhein 83
Santa Clara 83
Dearborn 70
Tulsa 64
Beijing 61
Brussels 55
Milan 53
Jinan 45
London 42
Nuremberg 42
Changsha 39
Kitzingen 39
Nanchang 36
Bremen 34
Los Angeles 34
Shenyang 33
Council Bluffs 29
Tianjin 29
Hebei 28
Abidjan 26
Kumar 26
Vienna 25
Falls Church 22
Jiaxing 22
Saint Petersburg 22
São Paulo 22
San Paolo di Civitate 21
Seongnam 21
Phoenix 20
Pune 20
Redwood City 20
Tehran 19
Guangzhou 17
Venice 17
Dallas 16
Kilburn 16
San Mateo 16
Chicago 15
Zhengzhou 15
Hangzhou 14
Ningbo 14
Turin 14
Verona 14
Auburn Hills 13
Frankfurt am Main 13
Taiyuan 13
Tashkent 12
Lappeenranta 11
Naples 11
Sofia 11
Toronto 11
Berlin 10
Izmir 10
Amsterdam 9
Falkenstein 9
Istanbul 9
Kunming 9
Volla 9
Washington 9
Aversa 8
Buffalo 8
Central 8
Columbus 8
Düsseldorf 8
Erbil 8
Moscow 8
Taizhou 8
Tappahannock 8
Messina 7
Rio de Janeiro 7
Edinburgh 6
Haikou 6
Olomouc 6
San Francisco 6
Amman 5
Totale 10.756
Salva come PNG Salva come JPEG
Nome #
Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic 325
4843delC of the BRCA1 gene is a possible founder mutation in Southern Italy (Sicily). 290
Founder mutations in BRCA1 and BRCA2 genes 209
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 207
Gastrointestinal stromal tumors (GISTs): focus on histopathological diagnosis and biomolecular features 204
One shot NEPA plus dexamethasone to prevent multiple-day chemotherapy in sarcoma patients 200
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 192
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 191
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer 177
Bisphosphonate-related osteonecrosis of the jaw (BRONJ): run dental management designs and issues in diagnosis. 174
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases 174
A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma 173
The role of Aurora-A inhibitors in cancer therapy. 168
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options 164
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 162
Surgical Treatment of Extravasation Injuries 161
Dedifferentiated retroperitoneal large liposarcoma and laparoscopic treatment: Is it possible and safe? The first literature case report 161
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. 159
The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers 158
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis 158
Antiemetic prophylaxis containing Palonosetron (P) alone or in combination with Aprepitant (A) in the treatment of advanced soft tissue sarcoma (STS) patients with epirubicin and ifosfamide 157
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 157
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 154
Ductal lavage: a way of carefully tracing the breast-secreting duct 153
Serum follistatin in patients with prostate cancer metastatic to the bone 153
Ductal lavage: a valid method of risk assessment and of early diagnosis in breast cancer. 152
A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy 152
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. 150
Lack of Correlation between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: A Retrospective Study 150
Clinical Impact of Cystatin C/Cathepsin L and Follistatin/Activin A Systems in Breast Cancer Progression: A Preliminary Report 148
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 148
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 147
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers 146
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 144
Activity and safety of temozolomide in advanced adrenocortical carcinoma patients 143
P16 ink4A, p53 alterations and S phase fraction are predictive of clinical outcome in laryngeal squamous cell carcinoma. 140
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 135
A case of squamocellular uterine cervix carcinoma metastatic to the skin with enterocutaneous fistula. 134
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients 134
Natural history of malignant bone disease in renal cancer: final results of an Italian bone metastasis survey. 133
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice 133
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. 132
Fatal heart failure induced by pazopanib in a sarcoma patient previously treated with gemcitabine 132
A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors 126
CT and MR imaging of chemotherapy-induced hepatopathy 125
Surgical treatment of primary gastrointestinal stromal tumors (GISTs): Management and prognostic role of R1 resections 124
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer 123
Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma? 122
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. 119
Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond 117
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone? 117
Ductal Lavage: a valid method of risk assessment and of early diagnosis in breast cance 114
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2 114
PML expression in soft tissue sarcoma: Prognostic and predictive value in alkylating agents/antracycline-based first line therapy. 108
PML down-regulation in soft tissue sarcomas 107
Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience 107
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. 106
A phase II study of Oxaliplatin Capecitabine chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 105
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 105
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 104
Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives 103
A phase II study of capecitabine oxaliplatin chemotherapy in metastatic breast cancer patients pretreated with anthracyclines and taxanes 102
Activin A and matrix metalloproteinase -2 and -9 blood levels as gauges of bone metastatic spread 102
Liquid Biopsy in Gastrointestinal Stromal Tumor 102
A “lymphocyte microrna signature” as predictive biomarker of immunotherapy response and plasma pd-1/pd-l1 expression levels in patients with metastatic renal cell carcinoma: Pointing towards epigenetic reprogramming 102
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study 102
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group 102
Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: Results from an international, multi-institutional, retrospective analysis 101
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes 101
Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives 99
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 97
Detection and clinical relevance of free-circulating tumor DNA in blood of patients with colorectal cancer. Proceeding of ICACT Fifteenth International Congress on Anticancer Treatment February 9th 12th 2004, Paris accepted for oral presentation 96
New potential circulating markers for the therapeutic monitoring of metastatic bone disease. 95
Gists eredo familiari e pediatrici: aspetti biomolecolari e clinici. 95
Mitotane concentrations influence outcome in patients with advanced adrenocortical carcinoma 95
ACTIVIN A CIRCULATING LEVELS IN PATIENTS WITH PRIMARY OSTEOPOROSIS OR BONE METASTASES FROM BREAST CANCER 94
Soft tissue sarcoma in Italy: From epidemiological data to clinical networking to improve patient care and outcomes 94
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma 92
PML down-regulation in soft tissue sarcomas. 92
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. 91
Weekly paclitaxel and Pegylated liposomal doxorubicin as first line treatment in metastatic breast cancer patients 88
Low dose oral chemotherapy for hormone refractory prostate carcinoma estramustine phosphate versus estramustine phosphate and etoposide. A Randomized phase II study of GSTU foundation 87
Activin A circulating levels in Patients with primary osteoporosis or bone metastases from brest cancer 86
Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study 86
Cardiotossicità e Cardioprotezione. 85
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib 84
Delaying surgery for patients with a previous SARS-CoV-2 infection 84
Weekly Paclitaxel (T) and pegylated liposomal Doxorubicin (PLD) as first line treatment in metastatic breast cancer (MBC) patients.VII CONGRESSO NAZIONALE G.O.I.M. ROMA 23-25 Giugno 2004 83
Effects of Zoledronic Acid on Cathepsin K circulating levels in patients with bone metastasis. 83
Erratum to: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis (Scientific Reports, (2018), 8, 1, (13379), 10.1038/s41598-018-30780-4) 83
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 83
Correction to: One shot NEPA plus dexamethasone to prevent chemotherapy-induced nausea and vomiting (CINV) in sarcoma patients receiving multiple-day chemotherapy (Supportive Care in Cancer, (2019), 27, 9, (3593-3597), 10.1007/s00520-019-4645-3) 81
Activin A circulating levels in patients with osteoporosis or bone metastasis from breast cancer 81
EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH COLORECTAL CANCER METASTATIC TO BONE 80
Gemcitabine plus metronoic capecitabine as second/third line chemotherapy in advanced adrenocortical carcinoma. A multicenter phase II trial. 79
Molecular characterization of a long-term survivor double metastatic non-small cell lung cancer and pancreatic ductal adenocarcinoma treated with gefitinib in combination with gemcitabine plus nab-paclitaxel and mFOLFOX6 as first and second line therapy 78
GIST, Tumori stromali gastrointestinali (Gist: linee guida diagnostico-terapeutiche) 76
Activin a and matrix metalloproteinase-2 and -9 blood levels as gauges of bone metastatic spread. In: Tumor microenvironment:Heterotypic interactions. 76
Duodenal perforation as presentation of gastric neuroendocrine tumour: A case report 76
Pegylated Liposomal Doxorubicin and weekly paclitaxel as first line treatment in metastatic breast cancer 75
Totale 12.668
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.055
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.055
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020702 0 0 0 0 0 0 0 0 0 257 325 120
2020/20212.257 104 188 191 197 242 142 161 162 229 213 235 193
2021/20221.903 101 339 80 61 87 73 98 109 189 252 158 356
2022/20232.475 274 490 70 275 225 350 181 203 230 22 94 61
2023/20241.315 51 142 98 107 90 229 193 100 25 42 30 208
2024/20252.414 100 227 233 303 150 238 409 335 265 154 0 0
Totale 16.203